The low-density lipoprotein receptor-related protein (LRP), which interacts with the Alzheimer disease (AD) β-amyloid precursor protein (APP), represents an important pathway in AD pathology. LRP-mediated receptor pathways appear to regulate both the production and the clearance of amyloid β-protein (Aβ), a principal neuropathological product in AD. Several conflicting studies have examined levels of LRP in AD brains, as well as the relationship between the LRP exon 3 (C766T) polymorphism and LRP levels and/or disease susceptibility. In order to further investigate the role of LRP in AD, we examined well-characterized brain samples collected from subjects with varying degrees of cognitive impairment for LRP protein expression levels as well as for the presence of the LRP exon 3 polymorphism. We found no correlation between LRP levels and either presence of the disease or cognitive decline. In addition, we found no correlation between the LRP exon 3 polymorphism and either AD or LRP levels.
|Number of pages||7|
|Journal||Journal of Neuropathology and Experimental Neurology|
|State||Published - 1 Oct 2003|
- Alzheimer disease
- LRP polymorphism
- Lipoprotein receptor-related protein (LRP)